A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.

被引：0
|
作者：
Pectasides, Dimitrios G.
Karavasilis, Vasilios
Kotoula, Vassiliki
Samantas, Epaminontas
Alexopoulou, Zoi
Zagouri, Flora
Syrigos, Konstantinos N.
Koureas, Andreas
Dionysopoulos, Dimitrios
Lazaridis, Georgios
Efstratiou, Ioannis
Apessou, Dimitra
Pentheroudakis, George E.
Papaxoinis, George
Fountzilas, George
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Athens, CT, Greece
[2] Hlth Data Specialists Ltd, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14563
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [23] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Eng, Cathy
    Nowara, Elzbieta
    Swieboda-Sadlej, Anna
    Tebbutt, Niall C.
    Mitchell, Edith
    Davidenko, Irina
    Stephenson, Joe
    Elez, Elena
    Prenen, Hans
    Deng, Hongjie
    Tang, Rui
    McCaffery, Ian
    Oliner, Kelly S.
    Chen, Lisa
    Gansert, Jennifer
    Loh, Elwyn
    Smethurst, Dominic
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4240 - 4250
  • [25] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [26] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Naoki Nagata
    Hiromichi Maeda
    Keiichiro Ishibashi
    Keiji Hirata
    Akitaka Makiyama
    Shigeyoshi Iwamoto
    Hiroyoshi Takemoto
    Mitsunobu Imasato
    Yoichiro Yoshida
    Yoshinori Munemoto
    Chihiro Tanaka
    Yoshitaka Morita
    Yoshihiro Hotta
    Atsushi Toyofuku
    Takeshi Nagasaka
    Satoshi Morita
    Junichi Sakamoto
    Hideyuki Mishima
    Medical Oncology, 2019, 36
  • [27] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Nagata, Naoki
    Maeda, Hiromichi
    Ishibashi, Keiichiro
    Hirata, Keiji
    Makiyama, Akitaka
    Iwamoto, Shigeyoshi
    Takemoto, Hiroyoshi
    Imasato, Mitsunobu
    Yoshida, Yoichiro
    Munemoto, Yoshinori
    Tanaka, Chihiro
    Morita, Yoshitaka
    Hotta, Yoshihiro
    Toyofuku, Atsushi
    Nagasaka, Takeshi
    Morita, Satoshi
    Sakamoto, Junichi
    Mishima, Hideyuki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [28] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [30] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
12345